Abstract: Pharmaceutically acceptable cholecalciferol sulfate salts are used for combating vitamin D3 deficiency. New cholecalciferol sulfate salts as well as pharmaceutical compositions of the pharmaceutically acceptable cholecalciferol sulfate salts are described as well.

Abstract: The present disclosure relates to methods of culturing algae that overcomes catabolic repression of photosynthesis in mixotrophic growth.

Abstract: The present invention is directed to pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.

Abstract: The present invention relates to a novel black garlic extract using garlic bulbs separated into six bulbs as a raw material instead of conventional whole garlic and a preparation method thereof. There is an excellent effect of providing a novel black garlic extract with various functionalities of high sweetness and high viscosity and improved flavor and reddish brown color as well as induce high-concentration conversion of 10 times or more to a S-allyl-cysteine compound in which a functional ingredient of raw garlic having antioxidation, reduction in blood cholesterol, improved liver function, and enhanced blood pressure is present in a small amount of 10 ppm or less by maximizing conversion of starch into reducing sugar for most preferably 15 days in a 90% to 100% saturated steam state and a liquefied enzymatic action temperature of 75° C. to 80° C. or lower without separate enzyme addition, and optimizing the action of proteases.

Abstract: The present disclosure provides a traditional Chinese medicine (TCM) composition for the treatment of cardiovascular and cerebrovascular diseases and use thereof, and belongs to the technical field of TCM. The composition for the treatment of cardiovascular and cerebrovascular diseases provided by the present disclosure includes the following raw materials: Radix Panacis Quinquefolii, Pheretima, Radix et Rhizoma Salviae Miltiorrhizae, Hirudo, Rhizoma Ligustici Chuanxiong, Rhizoma Gastrodiae, Fructus Crataegi, Stigma Croci, Herba Erigerontis, Semen Ginkgo, and Radix et Rhizoma Glycyrrhizae. The present disclosure treats the cardiovascular and cerebrovascular diseases through treatment based on syndrome differentiation and overall regulation in TCM; with less side effects, excellent efficacy, and fast acting, the present disclosure can achieve a stenting-free effect on the cardiovascular and cerebrovascular diseases.

Abstract: Disclosed is a new drug application of a Pithecellobium Clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter Baumannii (MDRAB), an MDR Pseudomonas Aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia Coli (ECO) and an ESBL-producing Klebsiella Pneumonia (KPN).

Abstract: Disclosed herein is pharmaceutical compositions of Compound 1, and/or the hydroquinone form thereof, and methods useful for treating or suppressing a disease or disorder such as an ?-synucleinpathy, a tauopathy, an autistic spectrum disorder, a pervasive developmental disorder, a liver disease, and liver damage in a subject using such pharmaceutical compositions.

Abstract: The present invention relates to processes for forming eutectic extracts, processes for purifying eutectic extracts and uses of the eutectic extracts such as in food-stuffs, pharmaceuticals, nutraceuticals and supplements, such as food supplements and sports supplements.

Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

Abstract: Disclosed are compositions including berberine combined with pea proteins and one or more surfactants. Also disclosed are processes for the preparation of the compositions, and the formulations and uses thereof.

Abstract: An improved method for the manufacture of a medicament, which method includes the use of tissues, larval forms or derivatives of insects that have been fed on a food containing pathogens.

Abstract: Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;

Abstract: A pharmaceutical composition comprises a Quisqualis indica extract as an active ingredient, for preventing or treating prostatic hyperplasia, and may also be used in a food composition. The Quisqualis indica extract may be used to treat and prevent prostatic hyperplasia by exhibiting effects of a reduction in prostate weight, a reduction in DHT as a prostatic hyperplasia inducing factor, and a reduction in prostate epithelial cell hyperplasia.

Abstract: The present invention provides an eye drop formulation in the form of a solution, comprising (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof; propylene glycol as a stabilizing agent; and a pH controlling agent in an aqueous medium, wherein the eye drop formulation has a pH ranging from 4.0 to 5.0. The eye drop formulation of the present invention can contain (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof in a high concentration; and has an excellent stability. In addition, the pharmaceutical product for preventing or treating macular degeneration according to the present invention can be stored for extended periods.

Abstract: The present invention relates to a GLP-1R receptor agonist compound and a use thereof. Specifically, the present invention discloses a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used for treating a metabolism-related disease, such as diabetes or nonalcoholic fatty liver disease, by means of activating GLP-1R receptors.

Abstract: Pyrido[3,4-b]indol-1-one compounds useful as antibacterial agents having the formula I: or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof, wherein R1, R2, R3, and R4 are as described herein. These compounds are effective in treating a bacterial infection in a patient.

Abstract: Methods of making mixed allergen products are provided, wherein the mixed allergen products are substantially free of replication viable organisms.

Abstract: In a system and process for selectively purifying various pharmacologically-relevant components of a source plant such as cannabis, an initial step provides a low-temperature, robust essential oil/terpene capture that also dehydrates and decarboxylates the starting product—fresh raw cannabis—by means of a vacuum-assisted microwave distillation process. By doing the terpene capture under vacuum distillation temperature may be kept low. The low distillation temperature maximizes yields of thermally-sensitive components such as terpenes and cannabinoids. The system includes an oil/water separator configured to prevent leakage of ambient air into the system.

Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition contains pemafibrate, a salt thereof or a solvate thereof in an amount of 0.017 to 4.2 mass % in terms of a free form of pemafibrate with respect to the total mass of the pharmaceutical composition.

Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.